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Abstract
Aims We aimed to use longitudinal data from an established screening programme with good quality assurance and
quality control procedures and a stable well-trained workforce to determine the accuracy of grading in diabetic
retinopathy screening.
Methods We used a continuous time-hidden Markov model with five states to estimate the probability of true
progression or regression of retinopathy and the conditional probability of an observed grade given the true grade
(misclassification). The true stage of retinopathy was modelled as a function of the duration of diabetes and HbA1c.
Results The modelling dataset consisted of 65 839 grades from 14 187 people. The median number [interquartile range
(IQR)] of examinations was 5 (3, 6) and the median (IQR) interval between examinations was 1.04 (0.99, 1.17) years. In
total, 14 227 grades (21.6%) were estimated as being misclassified, 10 592 (16.1%) represented over-grading and 3635
(5.5%) represented under-grading. There were 1935 (2.9%) misclassified referrals, 1305 were false-positive results
(2.2%) and 630 were false-negative results (11.0%). Misclassification of background diabetic retinopathy as no
detectable retinopathy was common (3.4% of all grades) but rarely preceded referable maculopathy or retinopathy.
Conclusion Misclassification between lower grades of retinopathy is not uncommon but is unlikely to lead to significant
delays in referring people for sight-threatening retinopathy.
Diabet. Med. 00, 000–000 (2016)
Introduction
Annual screening for diabetic retinopathy (DR) is recom-
mended for people with diabetes, with referral to ophthal-
mology clinics for people with sight-threatening retinopathy.
It has been put forward that screening intervals may be
extended using risk stratification [1]. One method for this
would be to use the results of two screening episodes to
stratify people by risk level and for those at lower risk, the
screening interval may be extended beyond a year. As part
of the screening process, digital photographs of the retina
are graded according to the degree of retinopathy from R0
to R3 and the presence of maculopathy (M0 or M1).
Grading is not a deterministic process and there is variation
between graders [2] and within graders [3]. Hence, screen-
ing can lead to misclassification of the true level of
retinopathy. Under-grading can occur because subtle abnor-
malities such as small microaneurysms or intraretinal
microvascular abnormalities are missed or graders may
downgrade or miss abnormalities. Over-grading may occur
because dust spots or pigment spots are graded as microa-
neurysms or minor abnormalities are mistaken for more
serious lesions.
Grading output can give the impression of change over
time (progression or deterioration) when the condition is
actually stable. This may have implications for screening
intervals, as people might have their screening interval
extended after apparently negative results when they should
have been screened more often or be screened annually when
they should have their screening interval extended. The
effectiveness of retinopathy screening programmes is affected
by the precision and accuracy of grading of photographs, but
direct estimation of misclassification rates has never been
Correspondence to: Jason L. Oke. E–mail: jason.oke@phc.ox.ac.uk
[The copyright line for this article was changed on 23 February 2016 after
original online publication]
This is an open access article under the terms of the Creative Commons
Attribution-NonCommercial License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited and
is not used for commercial purposes.
ª 2015 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. 1
DIABETICMedicine
DOI: 10.1111/dme.13053
attempted, and accuracy of screening is only usually reported
in terms of referable disease.
The aim of this study was to quantify the level of
misclassification in an established screening programme for
retinopathy with established quality control procedures
and a stable well-trained workforce using statistical
methodology, and to assess what effect misclassification will
have for screening programmes that plan to extend the
screening interval in people with no evidence of retinopathy.
Subjects and Methods
We obtained longitudinal data on retinal photographs from
2005 to 2012 from the Gloucestershire Diabetic Eye Screen-
ing Programme. Clinical risk factor data including duration
of diabetes, HbA1c and cholesterol, as well as the gender and
age of each subject were also obtained. The screening
programmes invites people for annual screening but some
people may attend less frequently. At each screening episode,
visual acuity was assessed using logMAR charts and colour
digital retinal photographs were taken of two standard 45°
fields (macula and disc centred) per eye after dilation of the
pupils. Photographs were then graded by trained assessors in
a central location for the presence of maculopathy and
retinopathy and the severity of retinopathy. The criteria for
grading has been described in detail elsewhere [1], but images
were graded by a primary grader and images with any level
of retinopathy were then graded by a second grader; 10% of
all images without retinopathy were second graded and
arbitrated by a third grader.
In the absence of a reference test or gold-standard measure
to represent the underlying true state of retinopathy at each
screening occasion, we used statistical models to estimate the
reference or true state using only the observed sequences of
screening grade and risk-factor data. The statistical model
builds on the results determined by screeners and graders and
attempts to gain an advantage over decisions made in real
time by considering all of the data across the whole cohort
over the whole period. To illustrate how it may be possible to
estimate the true grade in the absence of a gold-standard test,
imagine if we had a dataset of only one patient, graded many
times. If a patient is graded with high retinopathy at one visit,
no retinopathy at the next, then high retinopathy and then no
retinopathy and so on – we would suspect that the grading
process was inaccurate, even without having access to a gold
standard at any of these time points. In practice, we have a
dataset of many patients. The more patients there are with
apparent inconsistencies, the higher the estimated misclassi-
fication rate in the screening and grading. The model is a
mathematical ‘algorithm’ that, at its heart, does nothing
more than apply – and quantify – the above reasoning. In
order to operationalize the model, we defined a univariate
five-level outcome to represent five states in a model: (1) no
detectable retinopathy and no evidence of maculopathy in
either eye; (2) background retinopathy in one eye, no
detectable retinopathy in the other eye and no maculopathy
in either eye; (3) background retinopathy in both eyes both
without maculopathy; (4) maculopathy in at least one eye
and any retinopathy; and (5) pre-proliferative or proliferative
retinopathy in one or both eyes in the absence of maculopa-
thy (Fig. 1).
We treated these five levels of retinopathy and maculopa-
thy as states in a Markov model. Markov models have been
used extensively to model disease progression and to evaluate
cancer screenings strategies [4,5]. A hidden Markov model
(HMM) consists of a matrix representing the true disease
process as transition rates and a second matrix, the misclas-
sification matrix, representing the distinction between true
retinopathy state and retinopathy grade recorded by an
imperfect grading process; thus an HMM accounts for the
fact that the true disease state is not always reflected by the
test and may be misclassified [6]. We used a continuous-time
HMM to simultaneously estimate the transition rates
(intensities) between states and the probabilities of misclas-
sification [5]. We then used the model to retrospectively
estimate the true grade for each of the observed screening
grades.
The following modelling assumptions about the natural
progression of disease were made:
 as there is evidence to suggest that background retinopathy
can develop and subsequently disappear [7], movement
back and forth was permitted between states 1, 2 and 3;
 we assumed that eyes develop referable retinopathy or
maculopathy having developed background retinopathy,
hence there is no direct link from state 1 to the referable
states (4 and 5); and
 once disease has progressed to true referable retinopathy
or maculopathy, remission back to background retinopa-
thy (without treatment) is assumed impossible, hence the
referable states are absorbing states.
We did not constrain any misclassification probabilities.
The model therefore estimates a 5 9 5 matrix of instanta-
What’s new?
• A statistical modelling approach can be used to
retrospectively evaluate the accuracy of screening pro-
grammes for diabetic retinopathy.
• Our model predicts that misclassification of back-
ground retinopathy as no detectable retinopathy is
unlikely to lead to clinically significant delays in
referring people with sight-threatening retinopathy.
• This study adds to a growing body of evidence that
suggests screening intervals for people graded as no
background retinopathy could be safely extended to 2
or 3 years.
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neous transition probabilities with forced zero entries repre-
senting the modelling assumptions listed above and an
unrestricted 5 9 5 matrix representing misclassification
probabilities.
The model was fitted using themsm function [8] in R 3.0.2
[9]. Observations were excluded if retinopathy or
maculopathy grade were missing from either eye or were
obviously duplicate entries, and people were excluded if they
only had one useable observation or did not have a baseline
HbA1c, serum cholesterol or duration of diabetes recorded. A
number of different versions of the HMM were assessed,
adjusting transition rates for the duration of diabetes,
baseline HbA1c, age, gender and cholesterol. We considered
only the variables identified as important predictors in a risk
stratification model in a previous study [10]. The parameter
estimates relating to each of these covariates are equivalent
to hazard ratios for the risk of moving between states and are
constant over time. The final model was selected by starting
with one that included all available covariates and then
removing non-significant parameters. The fitted model was
then used to estimate the true grade of retinopathy for each
of the observed grades in the data. We used the Viterbi
algorithm [11] to calculate the true grade of retinopathy for
each person and each observation. The Viterbi algorithm is
an example of a dynamic programming method that aims to
find the most probable sequence of true states for any given
observation sequence [12]. How the Viterbi algorithm
estimates the most probable or estimated true sequence of
states or grades is best illustrated using a hypothetical
example. For an observed sequence of five screening images
say; O = {no DR, no DR, no DR, background DR in both
eyes, no DR}, the algorithm calculates a ‘score’ or probabil-
ity based on the observed sequence and one of many possible
true sequence (Q1, Q2, Q3 . . . Qk) using probabilities of
disease progression and misclassification informed by the
whole cohort. The algorithm then selects the true sequence
with the highest score or probability. In this hypothetical
example, if the version of the true sequence in which there
was no change, i.e. Q1 = {no DR, no DR, no DR, no DR, no
DR} had higher probability than any other sequence,
including the one that mirrors the observed set of results,
i.e. Q2 = {no DR, no DR, no DR, background DR in both
eyes, no DR}, then it would be selected over all other
explanations for the observed sequence. In this example, the
fourth observation of the sequence would be counted as
misclassified. We used this approach to estimate the misclas-
sification rate for the entire cohort (see Appendix Table A1).
We then identified people for whom the model algorithm
predicted background retinopathy in one eye (state 2) or
background retinopathy in both eyes (state 3) but were
observed as no detectable retinopathy (misclassified). We
then calculated the interval between the misclassified screen
and an observed referral level grade of either maculopathy
or retinopathy (state 4 or 5) if one occurred. We then
repeated this, counting people for whom both the observed
grade and estimated true grade were a level that warranted
referral.
Results
The results of 68 992 examinations for 14 810 people were
extracted from the screening service database. We excluded
623 people and 3153 observations because they had incom-
plete or unusable data. The remaining 14 187 people
(65 839 observations and 59 949 person-years of follow-
up) constituted the modelling cohort. The median number
[interquartile range (IQR)] of examinations in the modelling
cohort was 5 (3, 6). There were 8412 (57%) men, median
(IQR) HbA1c at baseline was 51 mmol/l (44–61 mmol/l)
equivalent to 6.8% (6.2% to 7.7%), median (IQR) age was
No detectable 
DR
State 1
Background DR
in one eye 
State 2
Background DR 
in both eyes
State 3
Pre-proliferative or 
proliferative DR in 
worse eye 
State 5
Any maculopathy 
and any DR  
State 4
FIGURE 1 Graphical representation of the transition model. Arrows from one state to another represent instantaneous transitions to be estimated.
Absence of arrows indicates instantaneous progression is not possible.
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64 (55–72) years and median (IQR) duration of diabetes at
baseline was 2.5 (0.8–7.3) years. Median (IQR) interval
between examinations was 1.04 (0.99, 1.17) years.
Table 1 shows the counts of transitions across all individ-
uals in the cohort. These are the number of times one grade
has been followed by another and does not take into account
misclassification or elapsed time. Row percentages are also
given and can be interpreted roughly as empirical probabil-
ities of observing changes in consecutive examinations.
The final model adjusted transition rates for duration of
diabetes and HbA1c. Cholesterol level, age and gender did
not independently affect transition rates (had non-significant
hazard ratios) and were dropped from the final model.
Table 2 shows the matrix of estimated transition intensities
or rates with their 95% confidence intervals. Diagonal
elements represent (minus) the rate or potential for leaving
the current state [13]. Off-diagonal elements are propor-
tional to the probabilities governing the next state. The
Table 1 Frequencies of successive states observed in the screening data
State
To
1 2 3 4 5
No detectable
retinopathy
Background retinopathy
in one eye
Background retinopathy
in both eyes
Referable
maculopathy
Referable retinopathy
(pre-proliferative or proliferative)
From 1 21 127 (76%) 4 694 (17%) 1 723 (6%) 191 (1%) 19 (0%)
2 4 630 (45%) 3 466 (34%) 1 854 (18%) 219 (2%) 44 (0%)
3 1 446 (16%) 1 608 (18%) 4 660 (53%) 784 (9%) 285 (3%)
4 162 (5%) 179 (5%) 582 (16%) 2 309 (64%) 349 (10%)
5 19 (1%) 18 (1%) 192 (15%) 357 (27%) 735 (56%)
From = previously observed grade. To = next observed grade.
Table 2 Fitted transition intensities matrix. Cells represent transition rates (95% CI)
States
To
1 2 3 4 5
No detectable
retinopathy
Background
retinopathy in one eye
Background
retinopathy in both eyes
Referable
maculopathy
Referable
retinopathy
(pre-proliferative
or proliferative)
From 1 0.11
(0.12 to 0.10)
0.11 (0.10 to 0.12) – – –
2 0.12 (0.10 to 0.14) 0.22 (0.25 to 0.19) 0.10 (0.09 to 0.11) 0.004 (0.002 to 0.007 0.00004 (0 to 0.007)
3 – 0.12 (0.10 to 0.14) 0.16 (0.18 to 0.13) 0.02 (0.02 to 0.03) 0.02 (0.01 to 0.02)
4 – – – 0 –
5 – – – – 0
Diagonal cells are minus the instantaneous rate of exiting the current state, off-diagonals are proportional to the probability of moving to
that state. Hence, 0.22 is the rate that people exit from the state 2 is 0.22 and the proportion leaving the current state in one year is 1  exp
(0.22) = 0.2. From leaving state 2, the next state would be background retinopathy in both eyes with probability 0.10/0.22 = 0.45 and no
retinopathy with probability 0.12/0.22 = 0.55
Table 3 Estimated error matrix
States
Observed grade
1 2 3 4 5
No detectable
retinopathy
Background retinopathy
in one eye
Background retinopathy
in both eyes
Referable
maculopathy
Referable retinopathy
(pre-proliferative or
proliferative)
Estimated
true grade
1 0.87 0.11 0.02 0.003 0.0001
2 0.21 0.55 0.22 0.02 0.002
3 0.006 0.03 0.84 0.10 0.02
4 0.002 0.007 0.06 0.85 0.08
5 0.002 0.005 0.10 0.23 0.67
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misclassification matrix of estimated error probabilities is
given in Table 3; here, off-diagonal elements represent
probabilities of grading errors, and diagonal elements prob-
abilities of correct grading.
We used the model to estimate the true state for each
observed grade in the data in order to assess the overall
accuracy of the screening program. In total, 14 227 grades
(21.6%) were estimated to be misclassified. Most of these,
10 592 (16.1% of the total), represented over-grading
(observed grade more severe than estimated true grade) and
3635 (5.5% of the total) represented under-grading (ob-
served grade less severe than estimated true grade). We found
1305 (2%) grades equivalent to false-positive referrals, i.e.
the observed grade was sufficient for referral when the true
grade was not, and 630 (1%) were false negatives, i.e. the
observed grade was non-referral but the estimated true grade
was referral level.
We then calculated the number of times background
retinopathy was under-graded as no detectable retinopathy.
We estimated that on 1997 occasions, people were observed
and graded as no detectable retinopathy (state 1) when their
true grade was most probably background retinopathy in one
eye (state 2), and on 245 occasions no detectable retinopathy
was observed when the model estimated that the true grade
was background retinopathy in both eyes (state 3). In all,
under-grading background retinopathy as no detectable
retinopathy represented 3.4% of all screening episodes.
Because there is a possibility that people being screened in
the future may have their screening interval extended when
no retinopathy has been detected (observed state 1), we
looked to see how many of the people under-graded in this
way went on to have referable retinopathy or referable
maculopathy and calculated the time between the misclassi-
fied grade and the referable grade. Of 1770 people who were
misclassified as no detectable retinopathy at least once, 151
were later observed as having referable maculopathy and 23
as having referable retinopathy. Of the 151 with referable
maculopathy, 40 (26%) were observed with maculopathy
within 2 years and 80 (53%) within 3 years of their initial no
detectable retinopathy grade. Of the 23 referrals for
retinopathy, 7 (30%) were observed within 2 years and 11
(48%) were observed within 3 years. Because misclassifica-
tion is also possible with referable disease, we repeated this
calculation taking into account the estimated true grade at
the time of the observed referral grade. Of the 151 with
observed referable maculopathy, only 31 (21%) also had
estimated true referable disease. Of the 23 with observed
referable retinopathy, 7 (30%) had estimated true referable
disease. This shows that for this particular subset of people
(observed with no detectable retinopathy and misclassified) a
referral grade within 3 years is more likely to be a false
positive than a true positive.
If we do not take into account possible misclassification of
the referral grade, 47 people would have experienced a delay
in referral (for either maculopathy or retinopathy) if their
screening interval had been extended to 2 years and this
figure would rise to 91 if the interval was extended to
3 years. If we take into account potential misclassification of
the referral grade, the number of people experiencing a delay
drops to 5 within 2 years and 20 within 3 years. Therefore,
42/47 (89%) and 71/91 (78%) represented false-positive
referrals. As a total of the entire follow-up of the study,
extending the screening interval to 2 years for people with no
detectable retinopathy would mean 8 per 1000 people
screened for 10 years experiencing a delay in referral due
to misclassification, and 15 per 1000 people screened for
10 years for a 3-year interval. Taking into account misclas-
sification, we estimate the number of delayed referrals
decreases to < 1 per 1000 people screened for 10 years for
2-year intervals and 3 per 1000 people screened for 10 years
for 3-year intervals.
Discussion
Our results show that misclassification of retinopathy in this
programme in this period may happen frequently (21.6%),
but occurs mostly between background (R1) in one or both
eyes and no detectable retinopathy. This screening pro-
gramme appeared to over-grade more than under-grade
(16.1% vs. 5.5%), and tended to over-refer (2%) rather than
under-refer (1%). This is of course a pragmatic and clinically
safe approach. Because under-grading may mean that some
people will have their next screening interval extended, we
looked to see how many would incur a delay in their referral
to specialist eye services. Although misclassification of
background retinopathy as no detectable retinopathy hap-
pens frequently, the nature of the progression of retinopathy
means that very few go onto true referable disease within 2
or 3 years. Our results suggest that extending the screening
interval for people with no detectable retinopathy at the last
screen to 2 years would result in very few delays in referral.
Delays in referral are likely to be very rare if the screening
interval is extended based on two consecutive screens with
no detectable retinopathy.
The significant advantage of this modelling approach to
evaluating the accuracy of a screening programme is in its
efficiency. Re-grading images as part of a quality control
approach is extremely valuable, but is expensive and time-
consuming and may not overcome the issues of between
grader variability or changes in staffing or grading protocols
(arbitration on R1/R0, for example). A modelling-based
evaluation approach could be applied to any screening
programme at minimal cost. The specific method we have
used (hidden Markov model) is able to take into account
that different screening programmes will have people with
different risk profiles and as a result it will be possible to
compare different screening programmes and identify pro-
grammes with higher proportions of under- and over-
grading both at the level of background and referable
disease.
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All models make assumptions and there are a number of
limitations to this approach. Significant violations to the key
assumptions of the model, namely, that sequences of screen-
ing results and subsequently the progression of retinopathy
can be described as a Markov process would probably
invalidate our results. As by the definition of the model, the
Markov process itself is hidden and not directly observable,
this means that it is not easy to check whether this
assumption holds true [14]. In addition, in order to obtain
working estimates, certain simplifications need to be made;
for example, we cannot estimate the likelihood of screening
missing or over-referring in the presence of both referable
retinopathy and maculopathy. We can, however, assess
whether predictions made by the model are reasonable and
in line with other estimates. We are also mindful that models
such as these can have alternative parameter estimates that
equally explain the observed data and that these could yield
significantly different estimates. However, we managed to
obtain estimates that are ‘maximum likelihood’, which
avoided having to arbitrarily choose between one of many
potential sets of estimates.
There also limitations that are not due to the approach itself,
and would be common to any method of evaluation. A
screening programme may not have access to all the relevant
patient clinical data or it may be too sparse. In our analysis, we
could not adjust for type of diabetes because there were not
enough people with Type 1 diabetes to obtain reasonable
estimates.However, in this case, diabetes type does not seem to
independently affect the risk of progression over and above
duration, HbA1c and status of retinopathy [1]. Finally, any
screening programme will have incomplete attendance and
this could, in theory, affect the evaluation of the programme,
especially if non-attendance is associated with grades of
retinopathy that are more prone to misclassification.
We compared 6-year progression rates predicted by our
model with those reported in the UKPDS 50 [15]. Our model
predicts that for those observed as no detectable retinopathy
at baseline, 37.8% will develop background retinopathy in
one or both eyes within 6 years, compared with 37.9% who
had no detectable retinopathy (10 10 using the ETDRS
classification) at baseline and ETDRS 20–35 retinopathy
6 years on in the UKPDS. Six-year progression rates from no
detectable retinopathy to referable retinopathy (ETDRS
> 43) were 2.77 (2.2% maculopathy) using our model and
1.5% in the UKPDS.
A direct comparison of our estimated misclassification
rates with external and independent estimates from the
literature is compromised by a lack of uniformity in grading
systems, differences in screening methods and the varying
case-mixes of people included in such studies. Estimates of
specificity and sensitivity from diagnostic accuracy studies
provide a useful, if somewhat limited, comparison with our
estimates because they only report misclassification of
referable disease. False-positive rates reported from studies
comparing mydriatic digital retinal photography with a
reference of either slit-lamp biomicroscopy or seven-field
stereo-photography varied considerably from as low as 1%
[16] to as high as 16% [17]. We estimated the percentage of
false-positive rates (1 – specificity) in this screening data to
be 2.2%. These estimates are similar to the false-positive
rates reported previously Scanlon et al. [18] and Stellingwerf
et al. [16] but much lower than in some other reports
[17,19,20]. There is also considerable variation in the false-
negative rates reported in the literature, ranging from 7%
[19] to 20% [18]. The false-negative rate predicted by our
model is 11.0%, which is towards the middle of the range of
false-negative rates reported in the literature [16–20].
More direct comparisons are possible with estimates of
misclassification derived directly from screening pro-
grammes. However, such reports are few and far between.
Healy et al. [21] compared retinopathy screening grading
and hospital eye services from the same screening pro-
gramme and reported that the screening service grades were
in agreement with hospital eye services in 76.9% of eyes.
This figure is close to the overall error rate (21.6%) estimated
by our model, but is only an approximation because the
hospital eye service does not necessarily represent a gold
standard. A more independent comparison can be made
between our estimates and those reported from regrading
images from other screening programmes. Manjunatha et al.
[22] reported that of the 2716 images initially graded as no
detectable retinopathy that they re-examined, 367 (13.5%)
were considered to have background retinopathy after
arbitration.
Looker et al. [23] previously used the same methodology
to model the potential impact of extending screening
intervals for retinopathy. The focus of their study was
different to ours, but they did publish their estimated
misclassification probabilities as supplementary web material
(ESM, table 6; available from http://link.springer.com/con-
tent/esm/art:10.1007/s00125-013-2928-7/file/MediaObjects/
125_2013_2928_MOESM7_ESM.pdf). Their error matrix
suggests that under-grading is more common than over-
grading in their screening programme, but to be sure of this,
one would need to know case-mix of retinopathy for the
people being screened. For example, Looker et al. estimate
that nearly half (49.2%) of all the people with observable
retinopathy or maculopathy are under-graded as having mild
background retinopathy in that screening programme.
Our modelling-based evaluation gives valuable insights
into the chance of correct or incorrect assignments (misclas-
sifications) from a screening programme for retinopathy and
shows that this approach could be used to evaluate and
compare other screening programmes. In these data, mis-
classification between lower grades of retinopathy is not
uncommon, but under the current recommendations for
annual screening, or if screening is extended to 2 or 3 years
for those with no retinopathy, it is unlikely to have a
significant effect on patient outcomes. Misclassification of
referable retinopathy into a lower grade is more of a concern
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as this means that opportunities to intervene are inevitably
delayed, which may be potentially harmful. Our findings
suggest that the false-negative rate is not insignificant and
could be as high as 11%; more work may need to be done
reduce this.
We have shown that it is feasible to use a model-based
approach to estimate the accuracy of a diabetic retinopathy
screening programme at an aggregate level. We believe this
method to be widely applicable and can be replicated
quickly, easily and at minimal cost. The model-based
evaluation could inform organizers of screening programmes
to identify problem areas and potential weaknesses in the
delivery of retinopathy screening.
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Appendix
Table A1 Actual number of misclassifications resulting from the Viterbi algorithm
States
Observed grade
1 2 3 4 5
No detectable
retinopathy
Background retinopathy
in one eye
Background retinopathy
in both eyes
Referable
maculopathy
Referable retinopathy
(pre-proliferative or
proliferative)
Estimated
true grade
1 33 668 5 098 1 113 187 24
2 1 997 7 082 2 781 238 26
3 245 388 6 430 687 143
4 36 48 315 3 195 295
5 9 15 207 375 1 237
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